[Paleopsych] Dave's Drug Regimen ; diary update of August 2005
Premise Checker
checker at panix.com
Sat Dec 17 16:54:57 UTC 2005
Dave's Drug Regimen ; diary update of August 2005
http://www.hedweb.com/diarydav/drug-regimen.html
[Can anyone evaluate this for me? Dave is David Pearce, if that means
anything.]
DP DRUG REGIMEN
Diary update, August 2005
[1]tablets of wisdom?
1 AUGUST 2005
What am I on?
100 mg [2]amineptine (Survector) and 2 x 5 mg [3]selegiline
(l-deprenyl, Eldepryl) daily. I also take omega3-rich flaxseed
[[4]linseed] oil supplements; [5]LEF's "Life Extension" mix; and
[6]resveratrol with [7]quercetin. And that's it - for now, at
least.
Amineptine increases exploratory behaviour in rats. Since taking
it, I have been seized by a desire to travel the [8]world. Climbing
[9]volcanoes in Indonesia, exploring [10]Machu Picchu, and
communing with [11]giant tortoises in the Galapagos Islands are
adverse side-effects not reported on the [12]product label. When at
home in England, I spend my days webmastering for the
[13]abolitionist project [my raison d'etre]; rocking autistically
to [14]pop music on my [15]iPod; or pushing back the frontiers of
knowledge in Borders' bookstore [16]Starbucks café - the haunt of
[17]Brighton's movers-and-shakers, its resident conspiracy
theorists, and anyone who needs a library that serves
industrial-strength black [18]coffee.
In spite of its dopaminergic action, I almost never bothered to try
amineptine in the first place. Not being a chemist, I assumed it
would have [19]dumb-drug antimuscarinic effects in virtue of its
being a [20]tricyclic. Amineptine is also devilishly difficult to
obtain. Colourful tales of King Rat, double-dealing Brazilian
lawyers, and a cast of characters plucked from a Tarantino movie
are probably best omitted here. However, I seem to have emerged
unscathed. In Rio, someone stole my [21]vegetarian shoes while I
was playing football on the beach; but anyone who needs to nick my
shoes probably deserves them more than I do.
Missing footwear aside, I've now prudently stockpiled plenty of
[22]amineptine for a rainy day. Frustratingly, Servier halted
production in Brazil in early 2005. So the global amineptine famine
is now worse than ever. Amineptine's ill-named abuse-potential i.e.
the extremely mild euphoria that follows for an hour or so after
ingestion, is weak and independent of its more subtle but
[23]sustained elevation of mood and motivation. As with
[24]nicotine or [25]caffeine, amineptine users typically learn to
self-titrate their intake for optimal effect: uncontrolled
dose-escalation is rare and self-defeating. I guess that
amineptine's acute action might be mildly tempting to teenagers
scouring the family home in vain for household products to swallow
or [26]sniff; but this was a childhood rite of passage I somehow
managed to skip.
After [27]Servier withdrew Survector in mainland Europe some years
ago, amineptine.com received a stream of sometimes heart-rending
emails from consumers, doctors and even [28]pharmacists who told us
it is was the only medication that worked: was there any way to
obtain an alternative supply? [Occasionally, we still get similar
plaintive emails from people who say the same about the
long-vanished noradrenaline and dopamine reuptake inhibitor
[29]nomifensine (Merital).] Short of ordering amineptine as a
"research chemical" via a chemical supply house, or
[30]synthesizing it via grandma's bathtub chemistry kit, the answer
was no. Even the usual [31]grey-market pharmacy sources on-line
dried up. This particular drug deficit was doubly frustrating here
at [32]BLTC HQ: Brighton is chemical capital of the UK, and if one
wanted to score truckloads of class-A euphoriants or psychedelic
[33]exotica, then one could do so (I am told) within an hour. But
sustainable mood-brighteners are thin on the ground. Until
tomorrow's designer genomes deliver invincible mental health for
all, there is a pressing need for rationally designed psychotropics
that are cheap, harmless and habit-forming. Admittedly, a marketing
slogan on the lines of "Addictive By Design" isn't the ideal
rallying-cry for a novel life-enriching pharmaceutical in today's
prohibitionist climate. If I had a teenage daughter, I'd probably
find myself chanting "Just Say No" too. But if a drug doesn't make
you want to take it again, then it probably isnt any good -
life-changing psychedelic epiphanies aside, and they might get
disruptive every day of the week.
Alas amineptine itself is no panacea. On the contrary, it's a dirty
third-rate stopgap, yielding a rather one-dimensional kind of
well-being suitable for a [34]Darwinian world. A
noradrenergic/dopaminergic drug regimen can lend a certain inner
tension to the psyche; it also makes one less introspective and
more outward-directed - something of a misnomer if one is only an
[35]inferential realist who believes that the so-called perceptual
world is just a toy simulation each mind-brain runs. At any rate,
amineptine is a [36]useful agent only because current alternatives
are so poor. One day, I hope to find something better. Most studies
of mood-brighteners confound the response of anxious and/or
agitated depressives with what may be known, somewhat
unflatteringly, as retarded melancholics. On this basis, amineptine
isn't statistically superior to other contemporary meds. For all
the heady talk of [37]pharmacogenetics and a new era of
"personalised medicine", [38]drug companies are loathe to encourage
"market segmentation" for fear of reduced profits. This reluctance
is misplaced: melancholics in particular don't do at all well on
current drug therapies. Indeed prescription psychotropics are
mostly so dire that anyone with a melancholic streak might be
better served by a blend of old-fashioned [39]Papaver Somniferum
and [40]coca leaves, despite their well-advertised [41]pitfalls.
Doctors bemoan the reluctance or inability of their [42]patients to
take their prescription meds as instructed; but this comes
perilously close to blaming the victim. "Patient compliance" is so
erratic because licensed "[43]antidepressants" are often
ineffective, side-effect-ridden or even actively [44]depressogenic.
Perhaps this dismal track-record isn't surprising. Investigational
drugs are tested to see if non-human animals will self-administer
them and discarded if they do - arguably not the smartest heuristic
for life-enhancement either for humans or our [45]horribly abused
cousins. Thus the so-called [46]antipsychotics, for instance,
frequently induce apathy, [47]dysphoria and generally [48]mess
people's heads up, albeit in ways that ensure their victims intrude
less on the lives of others. As it happens, a
neuroleptic/antipsychotic is one of the categories of drug I have
never felt brave enough to investigate. Somehow I doubt if there
will ever be a [49]PiHKAL for antipsychotics: devotion to the
experimental method has its limits. Once my capacity to do useful
webmastering for the abolitionist project is spent, however, I
dream idly about entering the Guinness Book of Records under the
category of world's greatest sustained euphoria - a form of
record-breaking unaccountably missing from today's roster of human
achievement. Goodbye depressive realism; hello [50]hedonistic
bliss. Of course, it's not going to happen; but I have fantasies of
implanting stem cells and nerve growth factors into my stunted
reward centres and expiring in my dotage from an uncontrolled
proliferation of pleasure cells. Does this bespeak a lack of moral
seriousness? Well, perhaps.
On a more sober note, I take [51]selegiline at a higher dosage (2 x
5 mg daily) than is (probably) optimal for [52]life-extension
purposes. The aim here is maximal selective inhibition of [53]MAO-B
for improved mood and motivation; but it's not [54]MAO inhibition
per se that accounts for selegiline's neuroprotective role, but its
[55]propargylamine moiety. This is borne out by the neuroprotective
action of the [56]S isomer of rasagiline, even though it's over
1000 times less potent as an MAO inhibitor. Selegiline, the older
drug I've taken for most of the past decade, will soon be available
at substantially higher and MAO-unselective dosages in the form of
controlled-release [57]EMSAM patch. Bypassing the gastrointestinal
tract avoids the need for dietary restrictions. I will probably try
EMSAM if my rasagiline experiment doesn't work out, though only at
a lower, relatively MAO-B selective dosage: agents with any kind of
serotonergic action [unlike MAO-B, MAO-A also breaks down serotonin
and noradrenaline] eventually make me listless. Instead, I need
drive, exuberance, "life force". Anything worthwhile in this world
- and most of its [58]horrors - has been achieved by
larger-than-life characters, defying adversity to triumph over
impossible odds. Unfortunately, I still undergo a
catastrophe-reaction if one of my cacti dies or a friend wrinkles
her nose in disapproval - not a good index of psychological
robustness if one wants to save the world. Fortunately for victims
of the syndrome in question, the Net offers hope to hormonally
challenged, smaller-than-life characters, in theory at least.
As an experiment, I intend shortly to substitute the novel "second
generation" [59]MAO-B inhibitor [60]rasagiline (Agilect, Azilect)
for selegiline. There is negligible evidence that selegiline's
trace amphetamine metabolic by-products occur in sufficient
quantities to exert any long-term adverse effects; but I would like
to explore MAO-B inhibited life without them. Hence the attraction
of [61]Professor Youdim's discovery. One reason for rasagiline's
lack of abuse potential/acute enjoyability may be the equivocal
role of [62]phenylethylamine (PEA). Several studies confirm PEA may
have an [63]antidepressant effect. It may serve as a
[catecholamine] "[64]enhancer". Yet PEA can also act acutely as an
endogenous anxiogen. This tallies with my own experience: a mild
anxiety or inner tension - occasionally amounting to [65]OCD-like
symptoms - ensues very shortly after taking selegiline. Some
subjects say they notice no subjective acute or chronic effects
while on it. Others report a slight elevation of mood and alertness
from the trace amphetamine [66]metabolites some three hours or so
after taking a tab. I most definitely fall into the latter category
too; and I can't believe it does me any long-term good.
My opinion of [67]rasagiline may be coloured by factors unrelated
to its [68]pharmacology. I was not wildly amused late last year to
be contacted by Israeli drug giant [69]Teva's lawyers threatening
the usual fire-and-brimstone over rasagiline.com if the domain
isn't surrendered to their client for a token sum. Virtual estate
stirs primitive territorial instincts, empire-building and the
baser human passions no less than its old-world physical
counterparts. Thus in tones more suitable for an unindicted
war-criminal, it is alleged that the international non-proprietary
name ([70]INN) in question should rightly be regarded as an
unregistered trademark of Teva. [If pharmaceutical companies were
as inventive in designing new drugs as they were in litigation then
we'd already all be in chemical nirvana] It is hinted darkly that
one might be a domain name [71]speculator rather than a corporate
branding strategist. Heaven forbid. On re-reading, my slightly
frosty reply might be misinterpreted to imply that accepting
sizeable amounts of cash from a drug company is a notion I find
almost physically too painful to contemplate. This is not in fact
wholly the case. Indeed on more than one occasion I have been
struck by the thought that drug companies have too much money and
we have too little. It would be nice to have our own private
research lab, for a start. But the way the industry aspires to
monopolise the pharmaceutical namespace to control information is
bad news for consumers ["patients"]. [72]Big Pharma will probably
succeed in capturing the namespace in the long run, whether by fair
means or foul. Certainly dot.com snobbery is a vice best suited to
those with deep pockets. [73]Gaboxadol, for instance, a
non-benzodiazepine GABA(a) agonist now in phase III clinical
trials, was once a part of the BLTC [74]portfolio. Gaboxadol is
being developed (with [75]Merck) by Teva's marketing partner, the
Danish-based [76]Lundbeck. So when a fellow rings up from Turkey
wanting gaboxadol.com "for my father's clothing business", I am
intrigued. His tale of his sick mother touches my heart. Two phone
calls later, however, he reappears in Denmark with the same ISP and
[77]Speednames registration-agent as Lundbeck - who will also, as
it happens, co-promote rasagiline with Teva. The plot thickens. If
drug companies will resort to such subterfuge to acquire a domain
name, then who knows what they might do with, say, hundreds of
millions of dollars at stake in a late-stage clinical trial.
Later this year, I may explore [78]agomelatine (Valdoxan). I'm
uncertain about the likely effect of its action as a [79]melatonin
receptor agonist. Will it just make me hypersomnolent during the
day? Nor do I really understand the implications of its action at
the 5-HT2b receptor. But agomelatine's role as an antagonist at the
serotonin [80]5-HT(2c) receptors is a bit more exciting. Blockade
of the 5-HT(2c) receptors [81]enhances frontocortical dopaminergic
and adrenergic activity - which is nice. Conversely, serotonin
5-HT(2c) receptor activation can be profoundly unpleasant.
Surprisingly perhaps, a drug combination of [82]BZP and the
5-HT(2c) agonist [83]TFMPP really is agreeably E-like, taken
acutely at any rate; but the effect of TFMPP on its own can be
dysphoria, depersonalisation and derealisation. [A
friend-of-a-friend tried TFMPP once and just curled up in a foetal
ball: not the ideal [84]serenic. I wonder, idly, how agomelatine
combines with BZP.] Despite my slight shift in neurobabble over
time, I still think in the language of receptor subtypes rather
than gene expression profiles. In a decade or two, this conceptual
scheme may seem almost as quaint as the idiom of [85]humoral
psychology, and laughably simple-minded; but we are creatures of
our time. In the more distant future, I suspect the ontology of the
[86]materialist paradigm will be overthrown, leaving only its
formal shell; and the world of pure consciousness will be
mathematically described by the harmonics of [87]superstrings or
their [88]braneworld cousins. But I guess this is the kind of
speculation best confined to one's [89]diary.
Nothing in my drug regime acts significantly to increase hedonic
capacity as distinct from motivation. The [90]mu-opioid receptor is
still taboo. However, at some stage I do at least want to add a
selective kappa opioid receptor antagonist to my dopaminergic
regimen [[91]kappa is the "nasty" opioid receptor; [92]mu is
rewarding]. Unfortunately, [93]nor-binaltorphimine, the prototype
selective kappa antagonist, is only weakly centrally active. In any
case, it's hard to find. In the meantime, my native cravings for
opioids must be satisfied by Darwinian social interactions.
[94]Cynics might claim this source is unreliable, adulterated,
expensive and of uneven quality; and true enough, I can barely
offer anyone a codeine tab's equivalent of reward myself. But one
way or another, we are all addicted. If I learned tomorrow that I
had only a few months to live, then I'd probably exit the world
with selective mu agonists to complement my regimen of
dopaminergics. [Shades of [95]speedballing or the [96]Brompton
cocktail]. With any luck, this kind of crude but enjoyable mix
won't be necessary. In a couple of decades or so, the first true
psychotropic wonderdrugs and somatic gene therapies should be
available. Rational design will replace serendipity. I hope so. If
one has tasted, say, the emotional release, self-insight and
empathetic bliss of pharmaceutically pure [97]MDMA, then it's hard
to accept the third-rate imitation of mental health bequeathed by
natural selection.
However, the immediate [98]product pipeline is thin. [99]Substance
P (NK1 receptor) antagonists aren't panning out as hoped.
[100]CRF(1) receptor antagonists are interesting, but they
[101]adversely affect intellectual performance. Broad-spectrum
"triple" reuptake inhibitors like [102]DOV 216,303 are promising
because they inhibit the reuptake of dopamine as well as
noradrenaline and serotonin; but heaven knows if and when they'll
get a product license. No one seems to be working on
[103]sustainable empathogen-entactogens - not even in the
scientific [104]counter-culture, let alone mainstream medical
science. And today's [105]opioids are all flawed. Yet in future,
when opioid [106]tolerance is eliminable, [107]sub-type selectivity
improved and [108]side-effects minimised, it's conceivable that
this demonised class will make a comeback both as tools for
life-enrichment and in psychiatric medicine - especially if the
rhetoric of the War On Drugs subsides. [At present, of course,
opioids are hard enough to access [109]lawfully even for serious
[110]pain-relief.] In particular, neuroactive opioids targeted on
sub-types of the [111]mu receptor could form the basis of some
spectacularly life-enhancing cocktails. Some day, I hope personally
to try a combination of a mu agonist and centrally active selective
kappa antagonist, together with a [112]peripheral antagonist to
minimise unwanted bodily side-effects. One of the greatest
discoveries this century, I think, will be identification the final
common pathway ([113]FCP) of pleasure, possibly downstream of a
subtype of the mu opioid receptor. In the late 20th century,
researchers had hoped they were homing in on the FCP in the
mesolimbic [114]dopamine system. This optimism proved
[115]premature. Incentive-motivation ["[116]wanting"] is
[117]dissociable from [118]liking. But the molecular signature of
pure pleasure holds the key to the universe, unlocking the power to
manufacture limitless value, meaning and [119]significance - magic
to infuse the [120]cosmos and all sentient life. Without the
pleasure-pain axis, nothing matters. It permeates and underlies our
entire conceptual scheme. [121]Utilitarians believe we just need to
delete the axis at one end and vastly [122]extend it at the other.
Will our descendants be hypersentient as well as superintelligent?
I think so. For sure, the search for long-lasting
experience-intensifiers can scarcely rank as morally urgent given
our malaise-ridden existence today. Understandably, millions
self-medicate with [123]alcohol to dull their awareness. Yet just
occasionally, I muse on the molecular machinery needed to churn out
hypervaluable experiences in ineffably delightful virtual worlds -
a prospect that isn't immediately obvious when wading through
literature about medium [124]spiny neurons in the rostral shell of
the [125]nucleus accumbens.
I would also like to find better ways of coping with [126]stress.
Although my consciousness has a harder-edged quality than that of
early drug-naïve DPs, I lack the strong-mindedness and resilience
that might be conferred by taking an [127]anabolic steroid.
[[128]DHEA is the nearest I've got to trying one of those. It had
the unwanted effect of increased libido, so I stopped.]
[129]Omega-3 essential fatty acid supplementation makes one feel
calmer; but it would be nice to feel serene. Whatever the cause,
intolerance of stress is not the ideal qualification for running a
[130]web hosting service. This holds true even if in practice one
is just the dead wood: it's the [131]sysadmin who keeps everything
humming. In truth, the historical origins of Knightsbridge Online
are less venerable than its imposing web shop-front might suggest.
Back when the web was young, I'd simply conjured up the most
snobbish-sounding name I could think of from the virgin [132]UK
namespace. Our chosen title was a bid to reassure KO's (few)
corporate clients, some of whom might be unsettled by the wilder
reaches of the BLTC websites, not to speak of the miscellaneous
anarchists, Buddhists, transhumanists and other exotic life-forms
populating the server. In reality, our London presence is exhausted
by the server at Telehouse; and the [133]picture of a corporate
head office on the KO's website bears a remarkable resemblance to
the Enron HQ. Oddly enough, the Knightsbridge brand sometimes leads
to confusion with our famous local corner-store. Every December,
for instance, we get contacted by miscellaneous high-net-worth
individuals wondering what has happened to their Christmas hampers
etc. Direct contact with Harrods itself has been more limited.
Several years ago, its Managing Director emailed asking if we could
change our [134]hotlink [on knightsbridge.co.uk] from Mr Mohamed Al
Fayed's [135]personal website to the [136]store site - an act that
must surely require a certain courage. Presented with such an
opportunity, any entrepreneur worth his salt would then have leapt
at the chance to discuss joint ventures, strategic partnerships,
etc. I just said yes, of course, and meekly complied. We remain
minnows in the corporate shark-pool. For now, at least, everything
seems [more-or-less] under control. Yet running a server entails
perpetual worrying about disaster scenarios. Thus we rent a box in
Texas that is used mainly for daily incremental off-site back-up.
So if a dirty bomb takes out Telehouse, our clients [and
[137]hedweb!] can rest assured that their sites will still be safe.
However, the reason we set it up originally was more mundane. The
controversial multi-level marketing firm [138]Herbalife objected to
a [139]website by a client on the server; and they went as far as
threatening our connectivity suppliers if we didn't remove the skit
in question. Quite what else might ever need to be exiled is
unclear. Perhaps [140]president-bush.com, currently registered to a
Mr Osama bin Laden [not sure about his politics; but he pays his
bills], or the lively anarchist rag [141]Schnews. Who knows.
How else would I like to change my ordinary Darwinian state of
consciousness? This is slightly more feasible than trying to change
the world. Earlier in my life, I experienced chronic angst tinged
with melancholia. Thankfully these have been chemically banished,
albeit not in favour of an irrepressible joie to vivre. I would
still like to eliminate various residual [142]atypical depressive
signs, notably rejection-sensitivity. But I'm not yet clear how;
I'm not going to take an [143]SSRI, and [144]5-HTP just makes me
lethargic. Rejection-sensitivity is especially irrational given my
[145]Matrix-style epistemology. The fate of my zombie avatars in
other people's [146]virtual worlds really shouldn't matter per se
any more than the fate of the zombies I zap in [147]Far Cry. Yet
the phantoms in my own little egocentric [148]world can be scarily
realistic - though I doubt if they can compete with the supernormal
stimuli in synthetic [149]VR games to come.
Either way, my desire for chemical self-improvement isn't entirely
self-interested. Upgrading my design-specifications would mean I
could do more for the [150]abolitionist project. Admittedly, I
think I could die happy knowing that [151]paradise-engineering has
secured a place on the lunatic fringe. But could one do more? At
present, the [small] percentage of [152]sympathisers who contact us
wanting to get actively involved just get deflected to a
[153]web-based strategy to win hearts and minds, or urged to
participate in the wider but disparate [154]transhumanist movement
- though sadly, only a [155]minority of transhumanists endorse
abolitionism [perhaps my predicting that posterity will view our
meat-eating habits as some sort of cannibalistic holocaust displays
a less than transhuman level of tact and diplomacy] But
organisation-building would involve mastering the dark arts of
intrigue, infighting and primate power-politics. These are mission
skills for which I am [156]ill-equipped. Regrettably, any
[157]post-Darwinian transition will depend on super-Machiavellian
apes, probably with far higher functional testosterone levels than
me. Whatever its organisational guise or ultimate idiom, the
abolitionist credo deserves to be shouted from the rooftops. I only
wish I could deliver barnstorming performances myself. Alas my
natural inclination is to hide from a hostile world full of
potential [158]predators and fearsome alpha males. My recent bouts
of wanderlust are a rare [159]drug-induced aberration. A
self-effacing manner is all very well and frightfully British; but
it isn't going to win over the unconvinced. In fact it's been said,
only half tongue-in-cheek, that it was our self-depreciating humour
that lost Britain the Empire. Whatever the case for overcoming
one's diffidence, my nagging suspicion is that
organisation-building is premature - though I deeply [160]admire
those who try to do so. If a broad power-elite consensus existed -
perhaps on the lines of putting a man-on-the-moon or the [161]human
genome project - then implementing any global blueprint for a
[162]cruelty-free world might take a century or so. Currently this
sort of timescale is sheer fantasy, or at least hugely optimistic.
On more sociologically plausible, incrementalist scenarios, the
[163]transition will take centuries, or even millennia. Only when
the [164]reproductive revolution of designer babies starts to
unfold in a few decades or so will the ethical dilemmas at stake
become real to most people. [e.g. Do I want to endow my prospective
kids with genes predisposing to depression, anxiety disorders or
malaise? etc]
This lazy biotechnological determinism chimes in all too well with
my passive temperament. Until the relevant technology matures, all
the high-falutin talk about transcending our biological heritage
etc., sounds mere science fiction - like pain-free [165]surgery
before [166]anaesthesia. Of course, history is littered with the
bones of people who thought their pet [167]nostrums were
inevitable. Could one's own life be no less absurd? Yes, quite
possibly. But might it be absurd in the sense that its
[168]Bentham-plus-[169]biotech premise is too obvious to be worth
re-stating - like a fellow who walks around with a sandwich-board
all day proclaiming the world is round rather than flat? Perhaps;
but this is the kind of absurdity I could live with.
* * *
[170]The Hedonistic Imperative
[171]HOME
[172]DP Diary
[173]Interview
[174]Interview 2
[175]Future Opioids
[176]Utopian Surgery?
[177]Wirehead Hedonism
[178]The Good Drug Guide
[179]The Pinprick Argument
[180]MDMA: Utopian Pharmacology
[181]Critique of Huxley's Brave New World
E-mail Dave
[182]dave at hedweb.com
References
1. http://www.hedweb.com/diarydav/welcome.htm
2. http://www.amineptine.com/
3. http://www.selegiline.com/
4. http://www.biopsychiatry.com/lipidsmood.htm
5. http://www.lef.org/
6. http://nootropics.com/resveratrol/neuroprotectant.html
7. http://www.nootropics.com/quercetin/index.html
8. http://www.huxley.net/organic.htm
9. http://www.sanur.org/indonesia/mount/bromo.html
10. http://www.hedweb.com/diarydav/machu-picchu.html
11. http://www.tortoises-turtles.com/galapagos.html
12. http://www.amineptine.com/product-info/index.html
13. http://www.abolitionism.com/
14. http://www.hedweb.com/diarydav/4-5star.htm
15. http://www.apple.com/ipod/
16. http://www.hedweb.com/diarydav/borders-brighton.html
17. http://hedweb.com/brighton/jedi.html
18. http://nootropics.com/caffeine/faq.html
19. http://www.biopsychiatry.com/dumbdrug.htm
20. http://www.biopsychiatry.com/tricy.htm
21. http://www.vegetarian-shoes.co.uk/
22. http://www.amineptine.com/refs/index.html
23. http://www.amineptine.com/amineptinevfluox.html
24. http://www.biopsychiatry.com/tobacco/index.html
25. http://www.biopsychiatry.com/cafnic.htm
26. http://www.glue-sniffing.com/inhalants.html
27. http://www.servier.com/
28. http://www.biopsychiatry.com/online-pharmacies/
29. http://www.nomifensine.com/refs/
30. http://www.amineptine.com/synthesis/manufacture.html
31. http://www.yourpharmastore.com/
32. http://www.bltc.com/
33. http://www.brightoncity.com/martyrdom.html
34. http://www.utilitarianism.com/pinprick-argument.html
35. http://cns-alumni.bu.edu/~slehar/quotes/russell.html
36. http://www.amineptine.com/aminonset.htm
37. http://www.biopsychiatry.com/pharmacogenetics.htm
38. http://www.biopsychiatry.com/drugcompanies/index.html
39. http://www.opioids.com/images/opium-poppy.html
40. http://www.cocaine.org/cocaleaves.html
41. http://www.opioids.com/timeline/index.html
42. http://www.hedweb.com/bgcharlton/sdtm.html
43. http://www.biopsychiatry.com/refs/index.html
44. http://www.biopsychiatry.com/melser.htm
45. http://www.animal-rights.com/
46. http://www.biopsychiatry.com/antipsychotics.html
47. http://www.biopsychiatry.com/neuroleptics.htm
48. http://www.hedweb.com/bgcharlton/atypical-neuroleptics.html
49. http://www.mdma.net/alexander-shulgin/pihkal-tihkal.html
50. http://utilitarianism.com/hedonism.html
51. http://www.selegiline.com/refs/
52. http://www.selegiline.com/deplong.html
53. http://www.selegiline.com/review.htm
54. http://www.selegiline.com/mao.html
55. http://www.selegiline.com/propargylamines.html
56. http://www.rasagiline.com/neuroprotective.html
57. http://www.selegiline.com/article/emsam.html
58. http://www.amphetamines.com/adolf-hitler.html
59. http://www.rasagiline.com/mao-b.html
60. http://www.rasagiline.com/
61. http://www.nootropics.com/smartdrugs/future.html
62. http://www.selegiline.com/phenylethylamine.html
63. http://www.selegiline.com/pea.html
64. http://www.selegiline.com/enhancers.html
65. http://www.biopsychiatry.com/dopamocd.htm
66. http://www.selegiline.com/amphet.html
67. http://www.rasagiline.com/refs/index.html
68. http://www.rasagiline.com/pharmacology.html
69. http://www.tevapharm.com/
70. http://www.who.int/medicines/organization/qsm/activities/qualityassurance/inn/orginn.shtml
71. http://www.dnjournal.com/columns/cover070405.htm
72. http://www.biopsychiatry.com/bigpharma/bigpharma.html
73. http://www.biopsychiatry.com/gaboxadol.htm
74. http://www.bltc.com/bltc-research.html
75. http://www.merck.com/
76. http://www.lundbeck.com/
77. http://speednames.com/
78. http://www.biopsychiatry.com/agomelatine.htm
79. http://www.biopsychiatry.com/agomelatine-valdoxan.htm
80. http://www.biopsychiatry.com/valdoxan.htm
81. http://biopsychiatry.com/valdoxan.htm
82. http://mdma.net/tfmpp/tfmpp-bzp.html
83. http://www.biopsychiatry.com/tfmpp/index.html
84. http://www.biopsychiatry.com/serenanx.htm
85. http://www.general-anaesthesia.com/people/blood-letting.html
86. http://www.materialism.com/
87. http://www.superstringtheory.com/
88. http://en.wikipedia.org/wiki/M-theory
89. http://www.hedweb.com/diarydav/index.html
90. http://www.hedweb.com/opioids/opiates.html
91. http://opioids.com/kappa/depressive.html
92. http://opioids.com/mu/genepharm.html
93. http://opioids.com/kappa/kappa-antagonist.html
94. http://www.oxytocin.org/oxytoc/love-science.html
95. http://www.biopsychiatry.com/cocktail.htm
96. http://www.cocaine.org/
97. http://www.mdma.net/index.html
98. http://www.neurotransmitter.net/newdrugs.html
99. http://www.biopsychiatry.com/substancep-antag.htm
100. http://www.biopsychiatry.com/crf1-antagonists.htm
101. http://www.biopsychiatry.com/crfmem.htm
102. http://www.biopsychiatry.com/antidepressantbroad.htm
103. http://www.mdma.net/
104. http://www.designer-drugs.com/pte/12.162.180.114/dcd/chemistry/rhodiummirror.html
105. http://www.opioids.com/
106. http://www.opioids.com/tolerance/paincontrol.html
107. http://www.opioids.com/cogmood/subtypes.html
108. http://www.opioids.com/methylnaltrexone/index.html
109. http://www.opioids.com/offshorepharmacy/index.html
110. http://www.opioids.com/legal/criminalised.html
111. http://opioids.com/mu/interact.html
112. http://opioids.com/methylnaltrexone/structure.html
113. http://www.biopsychiatry.com/fcp.htm
114. http://www.biopsychiatry.com/dopamine-antidepressants.htm
115. http://www.wireheading.com/pleasure.html
116. http://www.wireheading.com/pleasure/wanting-liking.html
117. http://www.biopsychiatry.com/hyperdopaminergic.html
118. http://www.wireheading.com/pleasure/index.html
119. http://www.wireheading.com/hypermotivation.html
120. http://www.hedweb.com/object32.htm
121. http://www.utilitarianism.com/
122. http://www.hedweb.com/
123. http://www.paradise-engineering.com/misc/index.html
124. http://www.biopsychiatry.com/medium-spiny.htm
125. http://www.nucleus-accumbens.com/
126. http://moodfoods.com/misc/cold-soup.html
127. http://www.biopsychiatry.com/steroids/anabolic.html
128. http://www.biopsychiatry.com/dhea-antidepressant.htm
129. http://moodfoods.com/omega3/
130. https://www.knightsbridge.net/
131. http://www.sysadminday.com/
132. http://www.nominet.org.uk/
133. http://www.knightsbridge.net/faq/hq.html
134. http://www.knightsbridge.co.uk/
135. http://www.alfayed.com/
136. http://www.harrods.com/
137. http://www.hedweb.com/confile.htm
138. http://www.herbalife.com/
139. http://www.herbal-lies.com/
140. http://www.president-bush.com/
141. http://www.schnews.org.uk/
142. http://www.biopsychiatry.com/atypical.html
143. http://biopsychiatry.com/emotionalblunting.htm
144. http://www.biopsychiatry.com/5htp-supplements.htm
145. http://whatisthematrix.warnerbros.com/rl_cmp/phi.html
146. http://cns-alumni.bu.edu/~slehar/Representationalism.html
147. http://www.farcry-thegame.com/
148. http://www.huxley.net/organic.htm
149. http://www.vrsource.org/
150. http://www.utilitarianism.com/biotech.html
151. http://www.huxley.net/
152. http://www.hedweb.com/jon-martin/index.html
153. http://www.bltc.com/faq.html
154. http://www.transhumanism.org/
155. http://www.hedweb.com/object27.htm
156. http://www.mdma.net/ecstasy-honesty.html
157. http://www.hedweb.com/object26.htm
158. http://www.herbweb.net/
159. http://www.hallucinogens.com/lsd/francis-crick.html
160. http://www.abolitionist-society.com/
161. http://www.biopsychiatry.com/pharmacogenomics.htm
162. http://www.bltc.com/buddhism-suffering.html
163. http://www.hedweb.com/object31.htm
164. http://hedweb.com/object30.htm
165. http://www.general-anaesthesia.com/people/velpeau.html
166. http://www.general-anaesthesia.com/
167. http://www.hedweb.com/hedethic/interview.html
168. http://www.utilitarian.net/bentham/
169. http://www.paradise-engineering.com/biotechnology/index.html
170. http://www.hedweb.com/hedab.htm
171. http://www.hedweb.com/index.html
172. http://www.hedweb.com/diarydav/index.html
173. http://www.hedweb.com/hedethic/interview.html
174. http://www.hedweb.com/hedethic/interview.htm
175. http://opioids.com/
176. http://www.general-anaesthesia.com/
177. http://www.wireheading.com/
178. http://www.biopsychiatry.com/
179. http://www.utilitarianism.com/
180. http://www.mdma.net/index.html
181. http://www.huxley.net/
182. mailto:dave at hedweb.com
More information about the paleopsych
mailing list